Table 2.
Cox analysis of prognostic factors in MuBC patients in the training queue
| Characteristics | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age | ||||
| ≤ 52 | Reference | Reference | ||
| > 52 | 2.081 (1.514–2.862) | < 0.001* | 1.980 (1.437–2.728) | < 0.001* |
| Breast subtype | ||||
| HR+/HER-2− | Reference | |||
| HR+/HER-2+ | 1.028 (0.505–2.091) | 0.940 | ||
| HR−/HER-2+ | 0.613 (0.084–4.490) | 0.630 | ||
| HR−/HER-2− | 0.000 (0.000–infinity) | 0.951 | ||
| Unknown | 1.016 (0.670–1.541) | 0.940 | ||
| Stage | ||||
| I | Reference | Reference | ||
| II | 1.625 (1.097–2.408) | 0.015* | 1.682 (1.097–2.580) | 0.017* |
| III | 2.684 (1.690–4.262) | < 0.001* | 2.752 (1.382–5.479) | 0.004* |
| IV | 10.772 (5.321–21.808) | < 0.001* | 6.642 (1.962–22.491) | 0.002* |
| ER status | ||||
| Negative | Reference | |||
| Positive | 0.634 (0.373–1.077) | 0.092 | ||
| PR status | ||||
| Negative | Reference | |||
| Positive | 0.830 (0.576–1.195) | 0.316 | ||
| HER-2 status | ||||
| Negative | Reference | |||
| Positive | 0.994 (0.501–1.972) | 0.986 | ||
| Unknown | 1.044 (0.688–1.583) | 0.841 | ||
| Historic stage | ||||
| Localized | Reference | Reference | ||
| Regional | 1.309 (0.946–1.811) | 0.104 | 0.754 (0.483–1.177) | 0.213 |
| Distant | 5.382 (3.158–9.172) | < 0.001* | 1.449 (0.535–3.925) | 0.466 |
| Surgery | ||||
| BCS | Reference | Reference | ||
| Mastectomy | 0.997 (0.643–1.545) | 0.989 | 0.779 (0.478–1.270) | 0.316 |
| Radical | 2.069 (1.483–2.887) | < 0.001* | 1.343 (0.893–2.019) | 0.157 |
| Radiotherapy | ||||
| No | Reference | Reference | ||
| Yes | 0.741 (0.548–1.003) | 0.053 | 0.727 (0.511–1.036) | 0.078 |
HR hormone receptors, HER-2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, BCS breast-conserving surgery
*P < 0.05